Retatrutide (RT) 15 mg/vial — 10 Vials/Kit

Retatrutide, commonly abbreviated RT and identified by Eli Lilly’s development code LY3437943 (LY-3437943), is an investigational peptide designed as a triple hormone-receptor agonist, activating the GIP, GLP-1, and glucagon receptors. Lilly is currently studying retatrutide in Phase 3 clinical programs involving obesity, type 2 diabetes, cardiovascular and renal outcomes, knee osteoarthritis, obstructive sleep apnea, chronic low-back pain, and metabolic dysfunction-associated steatotic liver disease (MASLD).

For your requested 15 mg/vial × 10 vials/kit configuration, the nominal total peptide content is 150 mg per kit.

📋 Product Identification

PubChem lists retatrutide under CAS 2381089-83-2, with LY3437943 and LY-3437943 among its synonyms.

---

🧬 What Is Retatrutide?

Retatrutide is an investigational peptide developed by Eli Lilly. Its distinguishing feature is its three-way receptor activity.

Unlike compounds designed to act primarily through one receptor, retatrutide activates:

1. GIP — glucose-dependent insulinotropic polypeptide receptor
2. GLP-1 — glucagon-like peptide-1 receptor
3. Glucagon — glucagon receptor

Lilly describes LY3437943 as a biologic entity acting as a triagonist at these three receptors.

This mechanism is the foundation of ongoing research into how combined incretin and glucagon signaling may influence body weight, glucose metabolism, energy balance, and broader cardiometabolic outcomes.

Lilly currently describes retatrutide as an investigational once-weekly triple hormone receptor agonist. In clinical trials, it has been administered as a once-weekly subcutaneous injection.

---

🔬 How Retatrutide Works

1. GIP receptor activity

GIP is an incretin hormone involved in metabolic regulation. Activation of the GIP pathway is being studied for its contribution to glucose regulation and metabolic signaling.

2. GLP-1 receptor activity

GLP-1 is another important metabolic hormone. GLP-1 receptor signaling has been extensively investigated in relation to glucose regulation, appetite, gastrointestinal function, and body-weight regulation.

3. Glucagon receptor activity

Glucagon plays an important role in energy metabolism and glucose homeostasis. Retatrutide’s additional glucagon-receptor activity is one of the features that differentiates it from many other incretin-based investigational and approved therapies.

The combination of all three pathways makes retatrutide a triple agonist, rather than the scientifically inaccurate informal term “GLP-3.” Lilly specifically notes that “GLP-3” is not an appropriate scientific classification for retatrutide.

---

⚖️ Research Uses of Retatrutide

Retatrutide is being investigated across a broad range of metabolic and obesity-related conditions.

⚖️ 1. Obesity and Weight-Management Research

One of the major areas of retatrutide research is obesity.

In the Phase 3 TRIUMPH-1 study, Lilly reported substantial reductions in body weight among participants receiving retatrutide. At the 12 mg study dose, participants experienced an average 28.3% reduction in body weight at 80 weeks. These are clinical-trial results, not a guarantee of an individual’s response.

🩸 2. Type 2 Diabetes Research

Retatrutide is also being studied in people with type 2 diabetes and excess weight.

Lilly reported Phase 3 findings showing improvements in HbA1c and body weight in the TRANSCEND-T2D program.

❤️ 3. Cardiovascular and Renal Research

Researchers are studying retatrutide in people with obesity and established cardiovascular disease.

The TRIUMPH-3 study evaluated the efficacy and safety of once-weekly retatrutide in adults with obesity and established cardiovascular disease.

🦴 4. Knee Osteoarthritis Research

Retatrutide has also been studied in adults with obesity or overweight and knee osteoarthritis.

The TRIUMPH-4 study investigated retatrutide in this population, reflecting interest in the relationship between obesity, weight reduction and obesity-associated musculoskeletal conditions.

😴 5. Obstructive Sleep Apnea Research

Another research area is moderate-to-severe obstructive sleep apnea associated with obesity.

Lilly’s development program includes retatrutide studies examining this condition.

🧬 6. Metabolic Liver Disease Research

Retatrutide is also being investigated in metabolic dysfunction-associated steatotic liver disease (MASLD).

🦴 7. Chronic Low-Back Pain Research

Lilly’s current pipeline additionally lists chronic low-back pain as an area being investigated with retatrutide.

---

⭐ Why Researchers Are Interested in Retatrutide

The principal scientific attraction of retatrutide is its multi-receptor mechanism.

These are research characteristics and investigated effects, rather than claims that every purchaser will experience the same results.

---

📦 Understanding the 15 mg/vial × 10 Vials/Kit Configuration

Your product configuration is straightforward:

15 mg per vial × 10 vials = 150 mg total nominal peptide content.

Product configuration

The 15 mg/vial specification is a product-content specification, not a recommended clinical dose.

It is important not to imply that the entire 15 mg vial should be administered at once or that a 10-vial kit represents a particular treatment course. Clinical dosing in trials involves specific protocols, dose-escalation schemes, participant criteria, and medical monitoring.

---

🧪 Product Quality Information

For an ecommerce product page, quality specifications should only be included when supported by your supplier’s actual documentation.

You may include information such as:

• 🔬 Purity
• 🧪 Certificate of Analysis (CoA)
• 🧬 Peptide identity
• ⚗️ Analytical testing
• 📦 Batch/Lot number
• 🧫 Endotoxin testing, where documented
• 💧 Residual moisture, where documented
• 🧪 Formulation
• 📅 Manufacturing date
• ⏳ Expiration/retest date

Avoid automatically describing the product as “99% pure,” “GMP,” “sterile,” “pharmaceutical grade,” or “clinically proven” unless you have documentation establishing those specifications.

---

📊 Detailed Product Description

Lilly states that retatrutide is not currently approved by the FDA and is available to participants through clinical trials while its safety and efficacy continue to be evaluated.

---

⚠️ Important Safety and Regulatory Information

Because retatrutide remains investigational, your product page should avoid presenting it as an approved medication.

Avoid claims such as:

❌ “FDA-approved weight-loss drug”
❌ “Guaranteed fat loss”
❌ “Guaranteed diabetes treatment”
❌ “Safe for everyone”
❌ “No side effects”
❌ “Approved medication”
❌ “Use this product to treat obesity”

More accurate language includes:

✅ Investigational peptide
✅ Research compound
✅ Triple GIP/GLP-1/glucagon receptor agonist
✅ Under clinical investigation
✅ Studied in metabolic and cardiometabolic research
✅ Not currently FDA-approved

Lilly’s July 2026 update stated that it planned to submit a Biologics License Application for retatrutide in Q1 2027, which further confirms that the compound remains in the investigational/development stage at present.

---

Retatrutide (LY3437943), also known as RT, is an investigational triple GIP/GLP-1/glucagon receptor agonist developed by Eli Lilly. This product configuration contains 10 individual vials specified at 15 mg per vial, providing 150 mg of nominal total retatrutide per kit. Retatrutide is being investigated in metabolic and cardiometabolic research, including obesity, type 2 diabetes, cardiovascular outcomes, MASLD, obstructive sleep apnea and obesity-associated conditions. For legitimate research purposes; not currently FDA-approved for general public use.

• Retatrutide 15mg,
• Retatrutide 15 mg vial,
• Retatrutide LY3437943,
• LY3437943 peptide,
• LY-3437943,
• RT 15mg,
• Retatrutide 10 vial kit,
• Retatrutide research peptide,
• Retatrutide research compound,
• GIP GLP-1 glucagon triple agonist,
• Retatrutide metabolic research,
• Retatrutide obesity research,
• Retatrutide type 2 diabetes research,

In short: RT 15 mg/vial × 10 vials/kit identifies a package containing 10 vials, each specified at 15 mg, for 150 mg nominal total content. The active compound is retatrutide (LY3437943), an investigational GIP/GLP-1/glucagon triple agonist currently undergoing clinical development.